Drug Profile
Methicillin-resistant Staphylococcus aureus infection therapeutic - HSRx Biopharmaceutical
Latest Information Update: 28 Jan 2020
Price :
$50
*
At a glance
- Originator HerbalScience Group
- Developer HSRx Biopharmaceutical
- Class Anti-infectives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Methicillin-resistant Staphylococcus aureus infections
Most Recent Events
- 28 Jan 2020 No recent reports of development identified for phase-I development in Methicillin-resistant-Staphylococcus-aureus-infections in Unknown (PO)
- 01 Dec 2016 Phase-I clinical trials in Methicillin-resistant Staphylococcus aureus infections (PO)
- 05 Aug 2015 HSRx Biopharmaceutical in-licenses 8 proprietary pharmaceutical products from HerbalScience Group